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Abstract
Angiodyplasia and aortic stenosis are both conditions that are highly prevalent in elderly people and 
can often co-exist. Recent studies suggest that this association is related to subtle alterations in plasma 
coagulation factors. The von Willebrand factor is the strongest link between aortic stenosis and bleed-
ing associated with gastrointestinal angiodysplasia. With an ageing population, the disease burden of 
aortic stenosis and its association with angiodysplasia of the bowel makes this an incredibly under-
diagnosed yet important condition. Clinicians should be aware of this association when dealing with 
elderly patients presenting either with unexplained anemia, gastrointestinal bleeding or with aortic 
stenosis. A high index of suspicion and appropriate diagnostic techniques followed by appropriate and 
prompt treatment could be life-saving. No clear guidelines exist on management but surgical aortic 
valve replacement is thought to offer the best hope for long-term resolution of  bleeding. With a growing 
number of technological armamentarium in the management of such patients, especially with the advent 
of transcatheter aortic valve implantation, new options can be offered even to elderly patients with co-
morbidities for whom conventional surgery would have been impossible. (Cardiol J 2020; 27, 1: 72–77)
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Introduction
Angiodysplasia is one of the commonest re-
ported causes of gastrointestinal (GI) bleeding 
(GIB) in the elderly population [1]. It is an acquired 
submucosal arterio-venous malformation that 
arises during the ageing process due to the com-
bination of high stress and deficiency of collagen 
IV that supports the connective tissue in the GI 
wall [2]. This condition is often associated with 
aortic stenosis (AS) and may be referred to by its 
eponymous name, Heyde’s syndrome [1]. There 
remains an ongoing debate as to whether there 
is a genuine association or it is just coincidental 
because the mechanism connecting both patholo-
gies remains unclear. There is however, a general 
consensus that aortic valve replacement (AVR) in 
this setting terminates GI blood loss in the major-
ity of patients [3].
This paper aims at reviewing the evidence be-
tween aortic stenosis and anaemia with a particular 
focus on angiodysplasia.
Subheadings
Historical perspective
Heyde’s syndrome was first described in 1958 
by Edward Heyde following a series of 10 patients 
with AS and GI bleeding of unknown origin [1]. 
Subsequent reports have inferred GI angiodyspla-
sia especially in the right colon as a probable site 
of the bleeding but the exact association between 
AS and angiodysplasia remained unclear. Later, 
angiodysplasia of the stomach and duodenum was 
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reported in patients with AS as being a potential 
cause of recurrent unexplained massive upper 
GI hemorrhage. With the combined use of both 
angiography and endoscopy to identify GI lesions, 
AS associated with angiodysplasia has been thor-
oughly documented, and can include both upper 
GI and lower GI lesions, particularly right sided 
colonic lesions. 
It was not until 1992 that an etiopathogenic 
mechanism was postulated. According to War-
kentin et al. [4], this phenomenon arises due to 
a deficiency of high molecular weight (HMW) 
multimeters of the von Willebrand factor (vWF). 
Type 2A von Willebrand disease appears to be the 
nexus between two components of this condition 
and is reported in as many as 67–92% of patients 
with severe AS [5].
Epidemiology
Anemia is a common finding among patients 
with severe AS. Rheude et al. [6] and Tjahjadi 
et al. [7] reported a 45% and a 30.1% prevalence 
of anaemia (World Health Organization definition) 
among patients undergoing surgical aortic valve 
replacement (SAVR) and transcatheter aortic valve 
implantation (TAVI), respectively. On the other 
hand, it has been postulated that the prevalence 
of calcific AS is much higher in patients with idio-
pathic GIB compared to non-idiopathic GIB and the 
general population. Several studies have reported 
a prevalence of 7–41% of AS with symptomatic 
GIB [7–10].
Godino et al. [11] elegantly showed that among 
400 consecutive TAVI patients (Nov 2007 till Feb 
2012), 37 patients had a history of GIB (9.2%). Of 
those, 7 (1.7%) patients had confirmed instrumen-
tal evidence of angiodysplasia and a final diagnosis 
of Heyde’s syndrome.
Pathophysiology
Several pathological mechanisms have been 
hypothesized to explain this condition and these in-
clude an age-related degenerative process, genetic 
predisposition and hematological abnormalities.
Age related degenerative process
This condition presents in patients of advanced 
age, usually in the seventh decade of life  (range 
53–90 years old) [11]. The bleeding is normally 
recurrent and potentially massive. Age dependant 
tissue deterioration is a known risk factor of both 
AS and angiodysplasia and the incidence of both in-
creases with age. Hence, angiodysplasia was thought 
to be due to senescence rather than AS per se [11].
Genetic predisposition
Heyde’s syndrome may be attributed to 
a common genetic predisposition for an underlying 
defect in connective tissue disease, particularly 
a deficiency of collagen type IV. Congenital connec-
tive tissue defects may aggravate age dependant 
tissue degradation essentially due to high tension 
and weak supporting tissue particularly in the 
colon [12]. Likewise, congenital abnormalities of 
the aortic valve, namely the bicuspid valve are 
other risk factors to induce calcification of the 
aortic valve [13].
Hematological abnormalities
Hematological disorders, especially defects 
of vWF can play a key role in Heyde’s syndrome 
[14]. vWF is a multimeric glycoprotein that con-
trols adhesion of platelets to the subendothelium 
of damaged blood vessels. Any cardiovascular 
disease that induces rapid clearance of HMW mul-
timers (multimers of vWF ≥ 10 dimers are known 
as HMW multimers) could cause bleeding from 
angiodysplasia. It is therefore understandable that 
the high shear in vasculature present in patients 
with AS is responsible for the decrease in size 
of the vWF mulitimers. Conversely, substantial 
improvement is noted in the amount of HMW 
multimers after surgical valve replacement [5] 
and TAVI [15, 16].
Other
Boss and Rosenbaum [16] described disten-
sion of intestinal mucosal vessels in post-mortem 
subjects with AS as the cause of GI blood loss. 
This reflex vasodilation is believed to be caused 
via the sympathetic system due to low-grade hy-
poxia. There is relaxation of the vascular smooth 
muscle, which with chronicity results in disten-
sion. It has also been postulated that in AS there is 
a redistribution of the splanchnic blood flow with 
associated mesenteric ischemia along with high 
intestinal intramural pressure. Pulse wave arte-
rial patterns in the final portion of the superior 
mesenteric conduit have shown a significant drop 
in arterial pressure in patients with AS compared 
to controls [17]. Ultimately the above pathological 
processes result in mucosal ischemia and bleeding 
due to loss of gut integrity.
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Clinical presentation
Most patients are elderly, more than 65 years 
old with known valvular heart disease or who have 
undergone heart valve replacement [11]. Patients 
with AS can present with unexplained chronic 
lower GIB which can cease and recur after sev-
eral years. Angiodysplasia can be diagnosed as an 
incidental finding in an otherwise asymptomatic 
patient with valvular heart diseases or who has had 
an acute massive hemorrhage [11]. Another pres-
entation is unexplained chronic iron deficiency [18].
Diagnostic modalities
Diagnosis remains a challenge because most 
patients do not exhibit generalized hemostatic 
deficit and bleeding is generally confined to GI 
tract but we believe that diagnosis should consist 
of a triad of cardiovascular, GI and hematological 
investigations.
Cardiovascular investigation
A transthoracic echocardiogram is the first 
line investigation to confirm the presence of AS 
and assess its severity. 
GI investigation
Colonoscopy, either alone, or alongside angi-
ography can be both diagnostic and therapeutic. 
Whenever feasible, colonoscopy and gastrodu-
odenoscopy are the initial diagnostic modalities 
of choice [19]. Selective mesenteric angiography 
may serve as a useful diagnostic technique for 
angiodysplasia, particularly in patients with a mas-
sive hemorrhage where a colonoscopic diagnosis is 
difficult. Before establishing a diagnosis of Heyde’s 
syndrome in an elderly patient with unexplained or 
unrevealed bleeding, other diagnoses such as GI 
malignancy, celiac disease, vitamin B12 or folate 
deficiency must be excluded. However, presence 
of angiodysplasia on sigmoidoscopy or colonoscopy 
should raise suspicions of Heyde’s syndrome par-
ticularly in patients with known echocardiographic 
evidence of AS or classical auscultatory findings 
of AS [19].
Wireless capsule endoscopy (CE) and double 
balloon enteroscopy (DBE) are newer techniques 
that allow diagnostic enteroscopy of the entire 
small intestine. CE is a painless, non-invasive 
procedure that facilitates visualization of the small 
intestine and indicates the route for enteroscope 
insertion [20]. However, CE is not a reliable 
method to detect all the lesions especially during 
active bleeding and does not offer a therapeutic 
intervention. DBE however can overcome the 
disadvantages of CE as it can visualize most of the 
small bowel by providing superior quality images 
compared to CE, enables diagnostic manoeuvres 
and therapeutic intervention such as achieving 
hemostasis, performing polypectomies, stricture 
dilatation and stenting. Radionuclide methods such 
as labelled red cell scintigraphy can also be used 
to image the GI tract over a prolonged period as 
GIB in this condition, whilst episodic is usually 
recurrent [21]. Endoscopic Doppler sonography 
has also been used to identify intestinal angiodys-
plasias and has also been used to indicate efficacy 
of treatment [22]. 
Despite significant advances in endoscopic 
technology as well as standardization of training 
and lesion recognition, the lesion can potentially 
be missed in about 35% of cases despite all inves-
tigations. Diagnostic laparotomy could be the only 
option and may be life-saving in such cases [23].
Hematological investigations
Heyde’s syndrome is usually associated with 
one of the acquired forms of vWF deficiency and 
the recommended guidelines for diagnosis and 
management which involves measurement of vWF 
levels. Immunoblot analysis or gel electrophoresis 
can detect a low level of HMW vWF multimers. 
vWF antigen levels and ristocetin co-factor activity 
are abnormal when where is severe deficit of the 
largest vWF multimers [24]. Likewise, patients 
with AS have a higher incidence of prolonged bleed-
ing time with an otherwise normal coagulation 
state compared to normal subjects. However, tests 
performed to detect von Willebrand diseases are 
not always confirmatory, as the abnormality may be 
subtle [24]. Moreover, multiple blood transfusions 
can also make vWF levels inconclusive [2]. 
Management
As of now, there are no recommended guide-
lines or universally accepted unified treatment or 
protocol for the management of Heyde’s syndrome. 
One should consult guidelines for management of 
unexplained GI blood loss, AS and vWF-deficiency 
before treating patients with Heyde’s syndrome. 
Therapeutic options for Heyde’s syndrome include 
AVR, surgery, angiographic intervention, double 
or single balloon endoscopy and medical therapy 
particularly hormonal and thalidomide treatment.
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Aortic valve replacement 
Aortic valve replacement is recommended as 
the first line treatment in this condition as it re-
duces or terminates GI blood loss [23]. Cessation of 
bleeding after AVR was found in 95% as compared 
to 5% managed by laparotomy with or without 
bowel resection [23]. Following AVR, it was also 
found that patients had improved levels of HMW 
multimers of vWF. AVR ameliorates mucosal blood 
supply and corrects the hematological abnormality 
[23, 24]. GI angiodysplasia could cease following 
AVR as shown by endoscopy, hence, elective GI 
surgery for bleeding angiodysplasias in patients 
with co-existing AS needs to be rescheduled until 
AVR has been attempted [25]. Moreover, in the 
presence of chronic anemia requiring multiple 
blood transfusions coupled with reduced levels of 
vWF, AVR should be considered even in asympto-
matic but hemodynamically significant AS patients 
[26]. Further studies are needed to clarify whether 
Heyde’s syndrome should be considered as an in-
dication for valve surgery in the absence of cardiac 
symptoms, anemia or GIB.
Valve replacement can result in almost im-
mediate cessation of bleeding and remission of 
GIB, a theoretically, mechanical valve replace-
ment warrants lifelong anticoagulation and this 
could promote GI bleeding from angiodysplastic 
lesions. Hence, biological valve replacement has 
been preferred over mechanical valves [27]. Some 
studies report no recurrence of bleeding in patients 
despite having had a mechanical valve with oral an-
ticoagulant therapy. Indeed, some authors suggest 
that choice between a biological and a mechanical 
valve makes no difference so long as AS is treated 
promptly and effectively [28].
Of note, patient-prosthesis mismatch and 
structural valve deterioration usually lead to recur-
rence of angiodysplasia and bleeding [29].
Transcatheter aortic valve implantation
The new paradigm shift in the management 
of AS, after the recent update of the European and 
American guidelines to include TAVI as a treatment 
option for intermediate risk cases, means that many 
of these patients will undergo TAVI rather than 
SAVR. However, very few studies have investigated 
the effect of using TAVI to treat patients with co-
existing HMW multimers of vWF and severe AS. 
Spangenberg et al. [30] enrolled 95 patients for 
elective TAVI of which 40 had abnormal multimers 
with 42% of these patients experiencing an average 
HMW multimers content of 16.2 ± 3.3%. TAVI led 
to a normalization of HMW multimers content in 
patients with prior abnormal multimers and also 
left HMW multimers in the remainder of the study 
population unaltered [30]. Similar findings were re-
ported by Caspar et al. [31] and Marggraf et al. [32]. 
Spangenberg et al. [30] did not show any increase 
in bleeding of transfusion requirements in patients 
with severe vWF deficiency undergoing TAVI as 
opposed to surgical valve repair.
Based on the above studies, one can assume 
that TAVI is likely to be a curative option for 
Heyde’s syndrome and its associated GIB just 
like SAVR. Godino et al. [11], as mentioned above, 
reported on 7 cases of Heyde’s syndrome that un-
derwent TAVI. Of those, one had failed TAVI due to 
access issues, the others had successful implants. 
A median follow up of 22 ± 15 months of this small 
group of patients demonstrated that no patients 
had recurrence of GIB and the only patient that 
had failed TAVI required repeated transfusions.
Para-valvular leak (PVL) post TAVI, yet again, 
is this treatment’s Achilles’ heel. PVL cases tend to 
have inferior HMW multimers recovery, and poten-
tially this could abate the potential curative effect 
TAVI has over Heyde’s syndrome [30]. Thus TAVI 
deserves consideration as the primary approach 
for patients with severe acquired von Willebrand 
syndrome or abnormal multimers. 
GI surgery/endoscopy 
Treatment of bleeding GI angiodysplasia may 
require surgical resection of the affected part or 
frequently endoscopic laser photocoagulation with 
good initial results but recurrence occurs in a third 
of patients. Previously, segmental bowel resection 
of angiodysplasia lesions was the recommended 
treatment for patients with Heyde’s syndrome. In 
the absence of any colonic abnormalities observed 
intra-operatively, a blind right colectomy was rec-
ommended [33]. Ogano et al. [34] highlighted the 
need for elective bowel resection once a restricted 
bleeding site had been identified in patients at high 
risk of cardiac surgery. However, bleeding recurs 
in about a third of patients possibly due to lesions 
elsewhere in the GI tract which continues or starts 
to bleed in contrast to patients who undergo AVR 
who usually have long-term durable remissions [34]. 
GI surgery is only recommended if hemorrhage 
persists after a period of observation in patients 
who have demonstrable vascular ectasia on selec-
tive mesenteric angiography. A few case reports 
have described massive GI hemorrhage after SAVR, 
hence this strategy might not be ideal treatment in 
every patient with Heyde’s syndrome [35].
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In patients deemed unfit for AVR or surgical 
resection, endoscopic management has been the 
mainstay of treatment. Endoscopic destruction is 
usually performed using non-contact techniques 
with APC considered superior to Nd:YAG laser 
treatment due to lower risk of perforation [36].
Medical management
Replacement of clotting factors, vWF supple-
mentations or Contact F (combination of vWF and 
factor VIII) can be effective for acute control of GIB 
[17, 18]. Other alternatives include desmopres-
sin, cryoprecipitate or the pan haemostatic agent 
recombinant factor VIIa transfusion that can aug-
ment circulating levels of vWF [37]. Other forms 
of medical therapy include use of somatostatin or 
octreotide that potentially reduces venous pressure 
in the portal venous system [38, 39]. This can aid 
in controlling bleeding, although the long-term 
benefit of Octreotide is still undergoing evaluation 
[40]. Hormonal replacement therapy in the form of 
low doses of ethinyl estradiol and norethisterone 
can reduce transfusion requirements by 50% [41]. 
However, the mechanism of action behind this 
remains unknown.  
Other
Angiographic embolization of the source artery 
of the bleeding site could be an option to surgery 
[41]. Some studies recommend this approach 
only for high-risk surgical patients while others 
argue that this procedure can be considered in 
all patients presenting with massive GIB. The 
endoscopic treatment of angiodysplasia in the 
form of electrocoagulation sclerotherapy and 
laser photocoagulation has been shown to be 
effective [42], however several treatment at-
tempts may be required due to a high bleeding 
recurrence rate.
Thus, angiography and embolization, whilst 
often used as a rescue approach for the manage-
ment of GIB following failed endoscopic therapy 
may have a larger role to play. 
Future work: Biomarkers predicting risk
The vascular growth factor, angiopoeitin-2 
which plays an important role in embryonic an-
giogenesis may also have a role as a biomarker in 
predicting patients at risk of bleeding. Angiopoei-
tin-2 levels (both serum and mucosal levels) have 
been found to be elevated in patients with sporadic 
small bowel angiodysplasia [43]. It remains to be 
seen whether these levels are affected by AVR.
Conclusions
The nexus between aortic valve stenosis and 
GIB still remains poorly understood. Its potentially 
life-threatening nature and uncertainty renders it 
a difficult condition to treat. However, a high index 
of suspicion must alert any clinician especially 
in the emergency department while treating an 
elderly patient with co-existing gastrointestinal 
hemorrhage and AS. A multi-disciplinary approach 
can be comprised of a gastroenterologist, cardiolo-
gist, cardiac surgeon and a hematologist to best 
treat such patients. Besides, further studies must 
be carried out to explore the pathophysiology and 
management options for this condition. 
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